Truvada Shortage: What Providers and Prescribers Need to Know in 2026

This clinical briefing is intended for prescribers managing patients on Truvada (emtricitabine/tenofovir disoproxil fumarate, FTC/TDF) for either HIV treatment or HIV pre-exposure prophylaxis (PrEP). It covers the current availability landscape, formulary trends, prescribing considerations, and resources to maintain patient access.

Current Availability Status

As of 2026, Truvada (brand) and generic emtricitabine/tenofovir disoproxil fumarate are not listed on the FDA Drug Shortage Database. National supply is stable, with multiple generic manufacturers supplying the market (Teva, Aurobindo, Cipla, Mylan, Strides, and others). However, providers should be aware of the following access dynamics that can affect your patients at the point of dispensing:

Brand Truvada volumes have dropped significantly. Q1 2026 IQVIA data shows approximately 4,400 brand Truvada prescriptions compared to ~461,000 for Descovy. Some retail pharmacies have reduced or discontinued standing inventory for brand Truvada.

Generic fragmentation at pharmacy level. Most retail pharmacies stock one or two generic manufacturers' versions. If your patient's insurance requires a specific manufacturer and that product is on backorder, the pharmacy may report "out of stock" even though the drug is broadly available.

Formulary variability. While the ACA preventive services mandate requires most commercial insurers to cover PrEP at zero cost sharing, implementation varies. Some plans prefer Descovy or a specific generic; some are updating formularies in response to newer PrEP options.

Pharmacology Recap: FTC/TDF Mechanism and Formulations

Truvada contains two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs): emtricitabine (FTC, a cytidine analogue) and tenofovir disoproxil fumarate (TDF, a prodrug for tenofovir). Both are incorporated into viral DNA and competitively inhibit HIV-1 reverse transcriptase, blocking HIV replication. FTC and TDF are excreted renally; dose adjustment is required for CrCl < 50 mL/min for HIV treatment and Truvada is contraindicated for PrEP when CrCl < 60 mL/min.

Available formulations (200/300 mg standard adult; weight-based pediatric strengths: 100/150 mg, 133/200 mg, 167/250 mg).

Boxed Warnings Providers Must Document

HBV exacerbation on discontinuation: Severe acute exacerbations of hepatitis B have occurred in HBV/HIV coinfected patients who discontinue FTC/TDF. Monitor hepatic function clinically and with labs for at least several months after discontinuation. Anti-HBV therapy may be warranted.

HIV resistance risk in PrEP setting: Drug-resistant HIV-1 has been documented when Truvada was initiated for PrEP in individuals with undetected acute HIV infection. Confirm HIV-negative status immediately prior to initiation and at least every 3 months during PrEP use.

Key Monitoring Parameters

Baseline and periodic: serum creatinine, estimated CrCl, urine glucose, urine protein; serum phosphorus in patients with CKD

PrEP: HIV-1 test every 3 months; STI screening per clinical schedule; assess adherence at each visit

HIV treatment: viral load, CD4 count, renal function per DHHS guidelines

Bone mineral density: consider DEXA in patients with history of pathologic fracture or other risk factors; counsel about TDF association with BMD decline

The 2026 PrEP Prescribing Landscape

Providers now have four FDA-approved PrEP modalities to offer eligible patients. Understanding the clinical distinctions matters for shared decision-making:

Generic Truvada (FTC/TDF): Most affordable oral option ($21–$30/month with coupon); approved for all indications including receptive vaginal sex; requires baseline and periodic renal and bone monitoring

Descovy (FTC/TAF): Better renal and bone safety profile; not approved for receptive vaginal PrEP; no US generic; ACA coverage mandate applies; step therapy sometimes required by plans preferring generic FTC/TDF first

Apretude (cabotegravir LA): Every-2-month IM injection; INSTI class; superior efficacy data vs. daily oral in cisgender women; no daily adherence required; requires in-office administration

Yeztugo (lenacapavir): Every-6-month SC injection; capsid inhibitor; near-100% efficacy in trials; approved 2024-2025; insurance coverage growing but still variable; requires starter regimen

Prescribing Tips to Prevent Access Gaps

Write prescriptions generically. For TDF-based PrEP, writing "emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg" (DAW-0) allows dispensing of any available generic, maximizing chance of fill.

Establish a specialty pharmacy relationship. HIV specialty pharmacies consistently stock all formulations and have staff experienced in prior authorization workflows. Referring patients to one preferred specialty pharmacy can eliminate most access issues.

Prescribe 90-day supplies when possible. Less refill frequency means fewer chances for a stockout to interrupt therapy. Most insurance plans allow 90-day supplies for chronic maintenance medications.

Enroll eligible patients in assistance programs proactively. Gilead's Advancing Access (copay up to $7,200/year for commercially insured) and Ready, Set, PrEP (free for uninsured PrEP patients) can be enrolled at initiation, before access becomes an emergency.

Key Drug Interactions to Review at Prescribing

Didanosine: TDF increases didanosine exposure — dose reduction required; monitor for ddI toxicity (pancreatitis, neuropathy)

Atazanavir: Coadministration reduces ATV exposure; must boost with ritonavir

NSAIDs: Concurrent high-dose NSAID use with TDF increases risk of acute renal failure, particularly in patients with pre-existing renal risk factors; avoid combination or monitor closely

HCV antivirals (ledipasvir, sofosbuvir combinations): May increase tenofovir exposure; monitor for TDF toxicity

Other FTC- or TDF-containing products: Never co-prescribe Truvada with Biktarvy, Genvoya, Stribild, Complera, Descovy, or other FTC/TDF combinations

medfinder for Providers

When patients are having trouble filling Truvada, consider using medfinder for Providers. medfinder calls pharmacies on patients' behalf to check stock, saving your staff the time of calling multiple pharmacies and allowing faster resolution of access issues.

For a complete patient-management workflow, see: How to Help Your Patients Find Truvada in Stock: A Provider's Guide.